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662.e1 The Journal of Thoracic and CarObjective: The purpose of the study was to determine the effects of aprotinin on (1)
renal function, (2) apoptosis and apoptotic signaling, and (3) the inflammatory
response of the kidney after ischemia-reperfusion injury.
Methods: Male rats underwent a sham procedure or left renal ischemia for 1 hour.
Rats were divided into three groups and received no reperfusion, reperfusion for 1
hour, or reperfusion for 24 hours. The animals undergoing ischemia received saline
solution alone or aprotinin (60,000 kIU/kg). At the end of the experiment, a sample
for serum creatinine was taken and the left kidney was harvested. The kidney was
analyzed for expression of tumor necrosis factor , interleukin 1, and interleukin
6 (enzyme-linked immunosorbent assay and reverse transcriptase–polymerase chain
reaction) and activation of p38 mitogen-activated protein kinase, caspase 3, and
caspase 8 (Western blot). The kidney was assessed for apoptosis with enzyme-
linked immunosorbent assay and by terminal deoxynucleotidyl transferase biotin–
deoxyuridine triphosphate nick-end labeling staining of tissue slides.
Results: Aprotinin significantly decreased the rise in serum creatinine and apoptosis
caused by ischemia-reperfusion. Aprotinin significantly reduced interleukin 1 and 6
messenger RNA production and showed a trend toward reducing tumor necrosis
factor messenger RNA production after ischemia. Aprotinin also significantly
reduced caspase 8 activation and showed a trend toward decreasing p38 mitogen-
activated protein kinase activation after 1 hour of reperfusion.
Conclusion: These results suggest that aprotinin provides protection from renal
ischemia-reperfusion injury. They also suggest that aprotinin may do so by affecting
apoptotic signaling and inflammatory cytokine production. Aprotinin is a potential
therapeutic measure in clinical situations where renal ischemia-reperfusion injury
can be anticipated, provided adequate heparinization is possible.
Renal ischemia-reperfusion leads to injury through many mechanisms, suchas calcium dyshomeostasis, oxygen free radical production, mitochondrialdysfunction, cytokine generation, and neutrophil sequestration and activa-
tion. The role of inflammation in this injury is being increasingly delineated.1-9
Aprotinin, a serine protease inhibitor, inhibits many enzymes, including those
involved in coagulation, fibrinolysis, and inflammation. Aprotinin has been used to
improve hemostasis and reduce the blood transfusion requirements in cardiac
surgery. Aprotinin has anti-inflammatory properties and reduces the injury produced
by leukocytes by inhibiting leukocyte hyperactivation,10 leukocyte integrin expres-
sion,11,12 and leukocyte extravasation.13 Aprotinin has also been shown to decrease
in vitro tumor necrosis factor (TNF)  production by macrophages,14 decrease
plasma TNF- levels in patients undergoing coronary artery bypass grafting,15 and
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undergoing cold storage.16 Aprotinin also has been seen to
decrease the production of interleukin (IL) 617 while in-
creasing the production of anti-inflammatory IL-10 in car-
diac surgical patients.18
Concern regarding the use of aprotinin has been raised
because it has been reported to increase renal dysfunction.19
Studies showed a significant number of patients to have a
greater than 0.5 mg/dL increase in serum creatinine with
aprotinin, but the increase was transient and did not lead to
clinically significant renal disease.20,21 Other studies and a
recent meta-analysis have shown no difference between
aprotinin and placebo in the incidence of renal failure after
coronary artery bypass grafting.22-24
Ischemia-reperfusion injury can lead to cell death by
necrosis or apoptosis. Prolonged renal ischemia leads to
necrotic cell death, whereas in animal models with shorter
periods of renal ischemia, apoptosis is the primary mode of cell
death.25 Aprotinin has been shown to reduce cardiomyocyte
apoptosis after myocardial ischemia-reperfusion injury,26 sug-
gesting the possibility of a similar effect in renal ischemia-
reperfusion.
The purposes of the study were to (1) determine the effect
of aprotinin on renal function after ischemia-reperfusion
injury, (2) examine the effects of aprotinin on apoptosis and
apoptotic signaling after ischemia-reperfusion injury, and
(3) determine the effects of aprotinin on the inflammatory
response of the kidney to ischemia-reperfusion injury.
Materials and Methods
Animals
Male Sprague-Dawley rats weighing 250 to 300 g (Harlan Sprague
Dawley, Inc, Indianapolis, Ind) were acclimated and maintained on
a standard pellet diet for 1 week before the initiation of experi-
ments. Animals were anesthetized with isoflurane. The animal
protocol was reviewed and approved by the Indiana Animal Care
and Use Committee of Indiana University. All animals received
humane care in compliance with the “Guide for the Care and Use
of Laboratory Animals” (http://www.nap.edu/catalog/5140.html).
Experimental Groups and Operative Techniques
Animals were divided into the following experimental groups: (1)
1-hour sham controls (n  5), (2) 2-hour sham controls (n  5),
(3) 25-hour sham controls (n  5), (4) 1-hour ischemia (n  12),
(5) 1-hour ischemia and 1-hour reperfusion (n  12), and (6)
1-hour ischemia and 24-hour reperfusion (n  12). Animals un-
dergoing ischemia were further allocated to receive either aproti-
nin at 60,000 kIU/kg or an equivalent volume of saline solution
through tail vein injection 15 minutes before initiation of ischemia.
Twenty-five hour sham controls (group 3) and animals undergoing
24-hour reperfusion (group 6) also received 1200 U/kg heparin
subcutaneously 30 minutes before laparotomy and underwent ne-
phrectomy of the right kidney. After induction of anesthesia, the
left renal pedicle was isolated through a midline laparotomy and
occluded with an atraumatic snare. The abdomen was subsequently
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reperfusion groups, the snare was removed externally without need
for abdominal reentry. The sham controls underwent the same
procedure without occlusion of the renal pedicle. On completion of
the experiment, the animals were anesthetized, serum samples
were taken, and the left kidney was removed. A portion of the
kidney was kept in 30% sucrose at 4°C for staining for apoptosis,
and the remainder was frozen in liquid nitrogen. The tissue was
stored at 70°C until further testing could be performed. All
animals were humanely killed.
Renal Function Analysis
To avoid the confounding, compensatory creatinine clearance of
the contralateral kidney, rats undergoing reperfusion for 24 hours
and the 25-hour sham controls underwent right nephrectomy at the
same time as the left renal ischemia. Serum for creatinine mea-
surement was taken at the end of reperfusion.
Apoptosis
Apoptosis in the kidney was assessed with a commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kit (Cell Death
Detection ELISAPLUS; Roche Diagnostics Corporation, Labora-
tory Systems, Indianapolis, Ind) that detects mononucleosomes
and oligonucleosomes. ELISA was performed according to the
manufacturer’s instructions. Results are depicted as enrichment
factor, the ratio of the sample value (in milliunits) to the negative
control (sham controls) value (also in milliunits). The tissue was
also examined for apoptosis with a commercially available kit
(DeadEnd Fluorimetric TUNEL System; Promega Corporation,
Madison, Wis). The kit is based on terminal deoxynucleotidyl
transferase incorporation of fluorescein–deoxyuridine triphosphate
for detecting DNA strand breaks in the nuclei of cells undergoing
apoptosis. The cell nuclei were then counterstained with bis-
benzimide to ensure constant cell density across all treatment
groups examined.
Western Blotting
Western blot analysis was performed to measure p38 mitogen-
activated protein kinase (MAPK), caspase-3, and caspase-8. Kid-
ney tissue was homogenized in cold buffer containing 20-mmol/L
tris(hydroxymethyl)aminomethane (pH 7.5), 150-mmol/L sodium
chloride, 1-mmol/L ethylenediaminetetraacetic acid, 1-mmol/L
ethyleneglycol-bis-(-aminoethylether)-N,N,N=,N=-tetraacetic acid,
1% Triton X-100 (Sigma-Aldrich Corporation, St Louis, Mo),
2.5-mmol/L sodium pyrophosphate, 1-mmol/L -glycerophos-
phate, 1-mmol/L sodium vanadate, 1-g/mL leupeptin, and
1-mmol/L phenyl methyl sulfonyl fluoride and centrifuged at
12,000 rpm for 5 minutes. The protein extracts (50 g/lane) were
subjected to electrophoresis on a 12% tris(hydroxymethyl)amin-
omethane hydrochloride gel (Bio-Rad Laboratories Inc, Hercules,
Calif) and transferred to a nitrocellulose membrane, which was
stained with naphthol blue-black to confirm equal protein loading.
The membranes were incubated in 5% dry milk for 1 hour and then
incubated with the following primary antibodies: p38 MAPK and
phospho-p38 MAPK (Thr180/Tyr182) antibody (Cell Signaling
Technology, Beverly, Mass) and caspase 3 (H-277) and 8 (H-134)
antibodies (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif),
followed by incubation with horseradish peroxidase–conjugated
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tion with Supersignal West Pico Stable Peroxide Solution (Pierce
Chemical Company, Rockford, Ill). Films were scanned with an
Epson Perfection 3200 Scanner (Epson America, Inc, Long Beach,
Calif), and band density was analyzed with TotalLab software (Non-
linear Dynamics Ltd, Newcastle upon Tyne, United Kingdom).
Reverse Transcriptase–Polymerase Chain Reaction
Total RNA was extracted from the kidney with RNA STAT-60
(Tel-Test, Inc, Friendswood, Tex). A 1.0-g sample of total RNA
was subjected to complementary DNA (cDNA) synthesis with
cloned AMV first-strand cDNA synthesis kit (Invitrogen Corpo-
ration, Carlsbad, Calif). The cDNA from each sample was used for
TNF-, IL-1, and IL-6 polymerase chain reaction (PCR) with
dual quantitative reverse transcriptase (RT) PCR kits (Maxim
Biotech, Inc, South San Francisco, Calif). One negative control
used double-distilled water instead of RNA sample, and a second
Figure 1. Renal function and apoptosis after 24 hours of reperfu-
sion. A, Serum creatinine levels in 25-hour sham controls (Sham),
1 hour of ischemia and 24 hours of reperfusion with saline
solution (I/R), and 1 hour of ischemia and 24 hours of reperfusion
with aprotinin (I/R  AP). B, Apoptosis ELISA in 25-hour sham
controls (Sham), 1 hour of ischemia and 24 hours of reperfusion
with saline solution (I/R), and 1 hour of ischemia and 24 hours of
reperfusion with aprotinin (I/R  AP). Results are depicted as
enrichment factor, ratio of sample value to negative control (sham
controls) value. Bars represent mean; error bars indicate SEM.
Asterisk indicates P < .001 relative to sham controls; delta
indicates P < .05 relative to ischemia-reperfusion with saline
solution.negative control used double-distilled water instead of RT, to
662.e3 The Journal of Thoracic and Cardiovascular Surgery ● Seexclude the presence of genomic contaminants. Positive controls
were included in the kit to verify appropriate expression of respec-
tive markers. PCR products were separated by electrophoresis on
1% agarose gel stained with ethidium bromide. Representative gel
photographs are shown, and densitometry was performed to assess
relative quantity, represented as a ratio to reduced glyceraldehyde-
phosphate dehydrogenase (GAPDH).
Renal TNF-, IL-1, and IL-6
Commercially available ELISA kits were used to determine kidney
homogenate TNF-, IL-1 and IL-6 content. TNF- and IL-6
contents were determined by BD OptEIA rat TNF ELISA set and
BD OptEIA rat IL-6 ELISA set (BD Biosciences, San Jose, Calif).
IL-1 was determined by Rat IL-1/IL-1F2 Duo set (R&D Sys-
tems, Minneapolis, Minn). ELISA was performed by adding 100
L of each sample (equal protein and tested in duplicate) to wells
in a 96-well plate. ELISA was performed according to the manu-
facturer’s instructions. Final results are expressed as picograms of
respective cytokine per milligram of protein.
Statistical Analysis
Data are presented as mean  SEM (n  5 to 6 animals in each
group). The experimental groups were compared by analysis of
variance with a post hoc Bonferroni-Dunn test and unpaired t tests.
Results
Renal Function
Serum creatinine was measured from uninephrectomized
rats (nephrectomy was performed at the same time as the
ischemia) at the end of 24 hours of reperfusion. Ischemia-
reperfusion resulted in marked renal damage, as demon-
strated by the increase in serum creatinine. Administration
of aprotinin resulted in a significant reduction in serum
creatinine (Figure 1, A).
Apoptosis
Apoptosis was assessed at the end of 24 hours of reperfu-
sion. Ischemia-reperfusion led to increased apoptosis, as
assessed by ELISA, which was significantly decreased by
the administration of aprotinin (Figure 1, B). Apoptosis was
also assessed by fluorescein TUNEL staining of the kidney,
which corroborated the findings of ELISA (Figure 2).
Renal Caspase Expression After Ischemia-Reperfusion
Injury
The expression of apoptosis-related caspases in ischemia-
reperfusion–injured kidney was assessed by Western blot-
ting. Caspase 8 expression was significantly higher after
ischemia, but aprotinin did not affect it. After 1 hour of
reperfusion, aprotinin significantly reduced caspase 8 ex-
pression (Figure 3, A and B). However, no difference was
observed in the expression of caspase 3 after ischemia or 1
hour of reperfusion relative to sham controls, and use of
aprotinin did not affect the response (Figure 3, C and D).
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Ischemia and reperfusion caused activation of p38 MAPK.
Aprotinin did not affect the activation caused by ischemia
but did show a trend toward decreased p38 MAPK activa-
tion after 1 hour of reperfusion (Figure 4).
Expression of TNF-, IL-1, and IL-6
ELISA and RT-PCR were used to assess the renal expres-
sions of TNF-, IL-1, and IL-6. Aprotinin caused a sig-
nificant reduction in the induction of IL-1 and IL-6 mes-
senger RNA (mRNA) caused by ischemia and showed a
trend toward decreased TNF mRNA production (Figure 5).
At the end of ischemia, no increase in cytokine protein
expression was observed (Figure E1). After 1 hour of reper-
fusion, aprotinin did not affect the induction of cytokine
mRNA (Figure E2) or cytokine protein expression (Figure
E3).
Discussion
The results of this study represent an initial demonstration
that aprotinin improves renal function and decreases ischemia-
reperfusion–induced apoptosis and apoptotic signaling after
renal ischemia-reperfusion injury. In contrast to the in-
creased serum creatinine that some clinical studies have
reported with aprotinin use in cardiac surgical patients, our
results show that aprotinin decreases serum creatinine after
renal ischemia-reperfusion injury. Adequate heparinization
plays an important role in preventing renal dysfunction after
cardiac surgery, and although most studies on aprotinin
have used standardized protocols for heparin administra-
tion, they have not provided data on clotting time. Many
Figure 2. Photomicrographs (original magnification 2
benzimide, blue) shows nonapoptotic cells; apoptosis
25-hour sham control, white arrow points to nonapop
white arrows point to apoptotic cells. C, In ischemia-r
totic cell.have postulated that aprotinin reduces the inflammation and
The Journal of Thoracic afluid overload associated with cardiopulmonary bypass sur-
gery, therefore relative to surgical controls, postoperative
serum creatinine levels are more concentrated in patients
receiving aprotinin. Another possible reason for the tran-
sient increase in creatinine caused by aprotinin may be the
filtering and reabsorption of aprotinin in the kidney. The
high dose of aprotinin might “overload” the kidney and
cause the increase in creatinine.19,23 In our study, the kidney
underwent ischemia-reperfusion injury, and it may be apro-
tinin’s anti-inflammatory properties that acted to provide
protection. Further support for the protective effects of
aprotinin in renal ischemia-reperfusion injury is provided by
the decreases in apoptosis and caspase 8. The decrease in
apoptosis that we observed is similar to the result obtained
by Pruefer and colleagues26 in the heart after regional
ischemia-reperfusion. Ozer and associates27 showed de-
creased epithelial necrosis and decreased inducible nitric oxide
synthase expression with aprotinin use after renal ischemia-
reperfusion injury. However, they did not assess renal function,
apoptosis, or renal inflammatory cytokine production.
The mechanism by which aprotinin mediates these pro-
tective effects is unclear. Aprotinin significantly reduced the
induction of IL-1 and IL-6 mRNA caused by ischemia. It
also led to a decrease in p38 MAPK activation after reper-
fusion. This indicates that aprotinin may reduce proinflam-
matory cytokine production, as has been shown in other
animal and clinical studies.14-18 However, we were not able
to find any difference with the use of aprotinin in the
expression of cytokine protein. This may mean that the
effect of aprotinin on the expression of cytokine proteins
demonstrating renal apoptosis. Nuclear stain (bis-
n (TUNEL assay, green) shows apoptotic cells. A, In
cell. B, In ischemia-reperfusion with saline solution,
fusion with aprotinin, white arrow points to nonapop-00)
stai
totic
epertakes longer to manifest. It also may mean that aprotinin
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Cardiopulmonary Support and Physiology Kher et alFigure 3. Active caspase protein expression in 1-hour sham controls (leftmost Sham), 1-hour ischemia with saline
solution (1hr I), 1-hour ischemia with aprotinin (1hr I  AP), 2-hour sham controls (rightmost Sham), 1-hour
ischemia and 1-hour reperfusion with saline solution (1hrI/1hrR), and 1-hour ischemia and 1-hour reperfusion with
aprotinin (1hrI/1hrR  AP). A, Representative immunoblot of caspase 8. B, Densitometric data of caspase 8 (as
percentage of GAPDH). C, Representative immunoblot of caspase 3. D, Densitometric data of caspase 3 (as
percentage of GAPDH). Bars represent mean; error bars indicate SEM. Asterisk indicates P < .01 relative to sham
controls; double asterisk indicates P < .05 relative to sham controls; delta indicates P < .05 relative to 1-hour
ischemia and 1-hour reperfusion with saline solution.
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nism. Renal ischemia-reperfusion causes endothelial activa-
tion and enhances endothelium-leukocyte interaction, re-
sulting in leukocyte accumulation and injury. In addition,
chemokines such as IL-8 and monocyte chemoattractant
protein 1 are upregulated, which by attracting leukocytes
may increase the injury produced. Aprotinin has been
shown to affect leukocyte integrin expression and leukocyte
extravasation and hence may provide protection in renal
ischemia-reperfusion injury through this mechanism. Fur-
ther studies looking at the impact of aprotinin on chemo-
kines and leukocyte-endothelium interaction may help to
clarify the mechanism of protection provided by aprotinin in
renal ischemia-reperfusion.
Our results show that aprotinin decreases apoptosis and
causes a significant reduction in caspase 8, suggesting that
the decrease in apoptosis may be mediated by altering the
expression of caspase 8. Caspase 3 is downstream to
caspase 8, and we did not find any significant increase in its
expression relative to sham controls, which may be because
Figure 4. The expression of activated p38 MAPK in 1-
saline solution (1hr I), 1-hour ischemia with aprotinin (
ischemia and 1-hour reperfusion with saline solution (1
aprotinin (1hrI/1hrR  AP). A, Representative immuno
bottom row shows phosphorylated p38 MAPK (activa
(percentage of total p38 MAPK). Bars represent mean; e
to sham controls; double asterisk indicates P < .05 reit is activated later. The importance in renal ischemia-
The Journal of Thoracic areperfusion injury of p38 MAPK, an important mediator for
both apoptosis and the production of proinflammatory cy-
tokines, has been shown by the use of p38 MAPK inhibi-
tors, which decrease TNF production and apoptosis and
provide protection from renal ischemia-reperfusion injury.2,28
We have shown that aprotinin decreases p38 MAPK acti-
vation and thus may be responsible for the decreased proin-
flammatory cytokines and the decreased apoptosis. How-
ever, JNK and ERK, the two other MAPKs, have also been
shown to increase after ischemia-reperfusion injury and
play an important role in apoptosis.29,30 Evidence suggests
that it may be the balance between p38/JNK and ERK that
determines the fate of the cell after stress. Thus, the role of
these MAPKs needs to be further evaluated to clarify the
mechanism by which aprotinin acts and the relative impor-
tance of each in producing apoptosis in renal ischemia-
reperfusion. Effects of aprotinin on ischemia versus those
on reperfusion indicate that aprotinin may impact ischemia-
reperfusion by at least two distinct mechanisms.
These results should be interpreted with certain caveats.
sham controls (leftmost Sham), 1-hour ischemia with
 AP), 2-hour sham controls (rightmost Sham), 1-hour
hrR), and 1-hour ischemia and 1-hour reperfusion with
Top row shows nonphosphorylated p38 MAPK (total);
B, Densitometric data of phosphorylated p38 MAPK
bars indicate SEM. Asterisk indicates P< .001 relative






lativAs is already known, once renal injury reduces the number
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accelerated rate. Longer follow-up is therefore needed to see
whether aprotinin is able to protect the nephrons from the
development of these chronic changes. Our study used 1
hour of ischemia, and we studied inflammatory mediators at
two time points. This provided data suggestive of a bene-
ficial effect of aprotinin on renal ischemia-reperfusion in-
jury. However, further studies that use different periods of
ischemia and examine multiple time points for cytokine
expression may help delineate the effects of aprotinin on
renal inflammatory response to ischemia-reperfusion injury
more clearly. Also, the use of inhibitors of p38 MAPK or
antibodies to TNF may help clarify the role these play in
mediating the protective effects of aprotinin on renal isch-
Figure 5. A1, B1, C1, Representative gel photographs de
bands in 1-hour ischemia with saline solution (1 hr I) a
C2, Densitometric data of TNF- (A2), IL-1 (B2), an
represent mean; error bars indicate SEM. Asterisk indiemia-reperfusion injury.
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Cardiopulmonary Support and Physiology Kher et alFigure E1. Renal TNF- (A), IL-1 (B), and IL-6 (C) protein levels expressed as picograms of cytokine per milligram
of protein in sham controls (Sham), 1-hour ischemia with saline solution (1 hr I), and 1-hour ischemia with aprotinin
(1 hr I  AP). Bars represent mean; error bars indicate SEM.662.e9 The Journal of Thoracic and Cardiovascular Surgery ● September 2005
Kher et al Cardiopulmonary Support and PhysiologyFigure E2. A1, B1, C1, Representative gel photographs depicting TNF- (A1), IL-1 (B1), IL-6 (C1), and GAPDH
RT-PCR bands in 1-hour ischemia and 1-hour reperfusion with saline solution (1 hr I/1 hr R) and in 1-hour ischemia
and 1-hour reperfusion with aprotinin (1 hr I/ 1 hr R AP). A2, B2, C2, Densitometric data of TNF- (A2), IL-1 (B2),
and IL-6 (C2) are presented as percentage of GAPDH. Bars represent mean; error bars indicate SEM.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 3 662.e10
Cardiopulmonary Support and Physiology Kher et alFigure E3. Renal TNF- (A), IL-1 (B), and IL-6 (C) protein levels expressed as picograms of cytokine per milligram
of protein in sham controls (Sham), 1-hour ischemia and 1-hour reperfusion with saline solution (1 hr I/1 hr R), and
1-hour ischemia and 1-hour reperfusion with aprotinin (1 hr I/ 1 hr R  AP). Bars represent mean; error bars
indicate SEM. Asterisk indicates P < .05 relative to sham control; double asterisk indicates P < .01 relative to
sham control.662.e11 The Journal of Thoracic and Cardiovascular Surgery ● September 2005
